Search results for: Karen S Pieper

Items from 1 to 20 out of 81 results

article

Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD‐AF registry

Jean‐Pierre Bassand, Saverio Virdone, A. John Camm, Keith A. A. Fox, more

Diabetes, Obesity and Metabolism > 25 > 10 > 3040 - 3053

Aims This study aims to describe both management and prognosis of patients with diabetes mellitus (DM) and newly diagnosed atrial fibrillation (AF), overall as well as by antidiabetic treatment, and to assess the influence of oral anticoagulation (OAC) on outcomes by DM status. Methods The study population comprised 52 010 newly diagnosed patients with AF, 11 542 DM and 40 468 non‐DM, enrolled...

article

Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD‐AF Registry

Frank Cools, Dana Johnson, Alan J. Camm, Jean‐Pierre Bassand, more

Journal of Thrombosis and Haemostasis > 19 > 9 > 2322 - 2334

Background Oral anticoagulation (OAC) in atrial fibrillation (AF) reduces the risk of stroke/systemic embolism (SE). The impact of OAC discontinuation is less well documented. Objective Investigate outcomes of patients prospectively enrolled in the Global Anticoagulant Registry in the Field‐Atrial Fibrillation study who discontinued OAC. Methods Oral anticoagulation discontinuation was defined...

article

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS

Michael A. Nauck, Darren K. McGuire, Karen S. Pieper, Yuliya Lokhnygina, more

Cardiovascular Diabetology > 2019 > 18 > 1 > 1-10

Background To examine the effects of the DPP-4i sitagliptin on CV outcomes during and after incident MI in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Methods TECOS randomized 14,671 participants with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) to sitagliptin or placebo, in addition to usual care. For those who had a within-trial MI, we analyzed...

article

Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis

Benjamin M. Scirica, Sameer Bansilal, Farideh Davoudi, Paul W. Armstrong, more

American Heart Journal > 2018 > 202 > C > 54-60

Although bradyarrhythmias have been observed with ticagrelor and its use with advanced atrioventricular block is not recommended, questions arise regarding its use in patients with mild conduction abnormalities. The objectives were to compare rates of clinically relevant arrhythmias in relation to any mild baseline conduction abnormality in patients with acute coronary syndrome randomized to ticagrelor...

article

Discharge timing and outcomes after uncomplicated non–ST-segment elevation acute myocardial infarction

Jennifer A. Rymer, Michael W. Tempelhof, Robert M. Clare, Karen S. Pieper, more

American Heart Journal > 2018 > 201 > C > 103-110

Length of stay after non–ST-segment elevation myocardial infarction (NSTEMI) continues to decrease, but information to guide duration of hospitalization is limited.We used landmark analyses, in which the landmark defined potential days of discharge, to estimate complication rates on the first day the patient would have been out of the hospital, and estimated associations between timing of discharge...

article

Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial

Matthew W. Sherwood, Renato D. Lopes, Jie Lena Sun, Danny Liaw, more

American Heart Journal > 2018 > 197 > C > 1-8

Patients with prior stroke are at greater risk for recurrent cardiovascular events post-acute coronary syndromes (ACS) and may have a different risk/benefit profile with antithrombotic therapy than patients without prior stroke.We studied 7391 patients with ACS from APPRAISE-2, stratified by the presence or absence of prior stroke. Baseline characteristics and outcomes of cardiovascular death, myocardial...

article

Unreliable Observations from a Confounded Analysis of a Skewed Database

Philippe Gabriel Steg, Robert A. Harrington, Anders Himmelmann, Stefan K. James, more

The American Journal of Medicine > 2017 > 130 > 8 > e355-e356

article

Corrigendum to ‘Association of Standard Clinical and Laboratory Variables with Red Blood Cell Distribution Width (RDW)’[Am. Heart J. (2016) 22–28]

Patrícia O. Guimarães, Jie-Lena Sun, Kristian Kragholm, Svati H. Shah, more

American Heart Journal > 2017 > 188 > C > 196

article

Association of standard clinical and laboratory variables with red blood cell distribution width

Patrícia O. Guimarães, Jie-Lena Sun, Kristian Kragholm, Svati H. Shah, more

American Heart Journal > 2016 > 174 > C > 22-28

Red blood cell distribution width (RDW) strongly predicts clinical outcomes among patients with coronary disease and heart failure. The factors underpinning this association are unknown.In 6,447 individuals enrolled in the Measurement to Understand the Reclassification of Disease of Cabarrus/Kannapolis (MURDOCK) Study who had undergone coronary angiography between 2001 and 2007, we used Cox proportional...

article

Pooled analysis of adverse event collection from 4 acute coronary syndrome trials

André Zimerman, Renato D. Lopes, Amanda L. Stebbins, Patrícia O. Guimarães, more

American Heart Journal > 2016 > 174 > C > 60-67

Adverse event collection in randomized clinical trials establishes drug safety. Although costly and regulated, it is rarely studied.Adverse event data from 4 clinical trials (APPRAISE-2, PLATO, TRACER, TRILOGY ACS) comprising 48,118 participants with acute coronary syndromes were pooled to compare patterns and determinants of reporting. Events were classified as serious (SAE) or nonserious (AE) from...

article

Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomes

John P. Vavalle, Sean van Diepen, Robert M. Clare, Judith S. Hochman, more

American Heart Journal > 2016 > 173 > C > 57-66

Among patients presenting with ST-segment elevation myocardial infarction (STEMI) for primary percutaneous coronary intervention (PCI), the associations between clinical outcomes and both baseline renal function and the development of acute kidney injury (AKI) have not been reported in a trial population with unselected baseline renal function.Patients enrolled in the APEX-AMI trial who underwent...

article

Predictors of contemporary coronary artery bypass grafting outcomes

Richard D. Weisel, Nancy Nussmeier, Mark F. Newman, Ronald G. Pearl, more

The Journal of Thoracic and Cardiovascular Surgery > 2014 > 148 > 6 > 2720-2726.e2

The study objective was to identify the predictors of outcomes in a contemporary cohort of patients from the Reduction in cardiovascular Events by acaDesine in patients undergoing CABG (RED-CABG) trial. Despite the increasing risk profile of patients who undergo coronary artery bypass grafting, morbidity and mortality have remained low, and identification of the current predictors of adverse outcomes...

article

No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial

Lars Wallentin, Richard C. Becker, Christopher P. Cannon, Claes Held, more

International Journal of Cardiology > 2014 > 176 > 1 > 300-302

article

Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: Serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013

Lars Wallentin, Richard C. Becker, Christopher P. Cannon, Claes Held, more

International Journal of Cardiology > 2014 > 170 > 3 > e59-e62

article

Challenges and Solutions to Pre- and Post-Randomization Subgroup Analyses

Manisha Desai, Karen S. Pieper, Ken Mahaffey

Current Cardiology Reports > 2014 > 16 > 10 > 1-8

Subgroup analyses are commonly performed in the clinical trial setting with the purpose of illustrating that the treatment effect was consistent across different patient characteristics or identifying characteristics that should be targeted for treatment. There are statistical issues involved in performing subgroup analyses, however. These have been given considerable attention in the literature for...

article

Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15years

Mark Y. Chan, Jie-Lena Sun, L. Kristin Newby, Yuliya Lokhnygina, more

International Journal of Cardiology > 2013 > 167 > 2 > 548-554

Data are limited on whether clinical trials have randomized higher-risk patients over time and how trends in risk profiles and evidence-based pharmacotherapies have influenced trial outcomes. We quantified changes in baseline risk, treatment, and outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) randomized in 9 phase 3 clinical trials of antithrombotic therapy...

article

Would Tirofiban Have Been Shown Non‐Inferior to Abciximab Had the TENACITY Trial Not Been Terminated for Financial Reasons?

PETER B. BERGER, JUDSON B. WILLIAMS, VIC HASSELBLAD, KAREN CHISWELL, more

Journal of Interventional Cardiology > 26 > 2 > 123 - 130

ObjectivesTo investigate whether tirofiban would have been non‐inferior to abciximab had the trial completed enrollment and place the termination of this trial in a broader research ethics context. BackgroundTENACITY was terminated by the sponsor for financial reasons. At the time, event rates for the 2 treatment arms were unknown. MethodsTENACITY was designed to compare tirofiban with abciximab...

article

Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention

Cynthia M. Westerhout, Karen S. Pieper, Stefan K. James, Kenneth W. Mahaffey, more

American Heart Journal > 2013 > 165 > 3 > 354-362.e2

Dynamic risk models update the risk profile of ST-elevation myocardial infarction (STEMI) patients over the acute period following the event and have implications to clinical practice and research.Multivariable survival models were developed in 5,745 STEMI patients undergoing primary percutaneous coronary intervention (PCI) enrolled in the APEX-AMI trial to predict 90-day mortality from 4 clinically...

article

Serious Infection After Acute Myocardial Infarction

Adriano A.M. Truffa, Christopher B. Granger, Kyle R. White, L. Kristin Newby, more

JACC: Cardiovascular Interventions > 2012 > 5 > 7 > 769-776

The aim of this study was to address the knowledge gap using the APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infarction) trial database. We also assessed the association between serious infections and 90-day death or death/myocardial infarction (MI).Little is known about the incidence, location, etiological organisms, and outcomes of infection in patients with ST-segment elevation myocardial...

article

Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial

Rajendra H. Mehta, Padma Kaul, Renato D. Lopes, Manesh R. Patel, more

American Heart Journal > 2012 > 163 > 5 > 797-803

Information on practice patterns and outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary interventions (PCIs) in Canada vs United States is limited.We evaluated differences in clinical and angiographic features, practice patterns, and outcomes between Canada and United States in 2,086 patients with ST-elevation myocardial infarction undergoing primary...

Publication date

Last 3 years (1)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

INFONA - science communication portal

Search results for: Karen S Pieper

Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD‐AF registry

Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD‐AF Registry

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS

Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis

Discharge timing and outcomes after uncomplicated non–ST-segment elevation acute myocardial infarction

Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial

Unreliable Observations from a Confounded Analysis of a Skewed Database

Corrigendum to ‘Association of Standard Clinical and Laboratory Variables with Red Blood Cell Distribution Width (RDW)’[Am. Heart J. (2016) 22–28]

Association of standard clinical and laboratory variables with red blood cell distribution width

Pooled analysis of adverse event collection from 4 acute coronary syndrome trials

Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomes

Predictors of contemporary coronary artery bypass grafting outcomes

No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial

Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: Serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013

Challenges and Solutions to Pre- and Post-Randomization Subgroup Analyses

Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15years

Would Tirofiban Have Been Shown Non‐Inferior to Abciximab Had the TENACITY Trial Not Been Terminated for Financial Reasons?

Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention

Serious Infection After Acute Myocardial Infarction

Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial

Filter options

Publication date

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: Karen S Pieper

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options